Anixa Biosciences (ANIX) Current Deferred Revenue (2011 - 2014)
Anixa Biosciences' (ANIX) quarterly Current Deferred Revenue came in at $1.2 million in Q2 2014, little changed YoY from $1.2 million in Q2 2013, and little changed on a QoQ basis from $1.2 million in Q1 2014.
Anixa Biosciences (ANIX) Current Deferred Revenue (2011 - 2014) Analysis & Trends
Anixa Biosciences (ANIX) has 4 years of Current Deferred Revenue data on file, last reported at $1.2 million in Q2 2014.
- Quarterly Current Deferred Revenue changed 0.0% year-over-year to $1.2 million in Q2 2014, while the trailing twelve-month figure through Apr 2014 was $1.2 million (changed 0.0% YoY) and the FY2013 annual result came in at $1.2 million, changed 0.0% from the prior year.
- Current Deferred Revenue held at $1.2 million in Q2 2014, from $1.2 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $2.6 million in Q3 2011 to a low of $1.2 million in Q1 2012.
- A 4-year average of $1.4 million and a median of $1.2 million in 2012 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2012 — Current Deferred Revenue sank 53.87% — and 2013, when it rose 0.03%.
- Tracing ANIX's Current Deferred Revenue over 4 years: stood at $1.6 million in 2011, then dropped by 27.81% to $1.2 million in 2012, then changed by 0.0% to $1.2 million in 2013, then changed by 0.0% to $1.2 million in 2014.
- The last three Current Deferred Revenue figures came in at $1.2 million (Q2 2014), $1.2 million (Q1 2014), and $1.2 million (Q4 2013), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Anixa Biosciences | 125.30 Mn | 125.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | 1.19 Mn |
| Jan 31, 2014 | 1.19 Mn |
| Oct 31, 2013 | 1.19 Mn |
| Jul 31, 2013 | 1.19 Mn |
| Apr 30, 2013 | 1.19 Mn |
| Jan 31, 2013 | 1.19 Mn |
| Oct 31, 2012 | 1.19 Mn |
| Jul 31, 2012 | 1.19 Mn |
| Apr 30, 2012 | 1.43 Mn |
| Jan 31, 2012 | 1.19 Mn |
| Oct 31, 2011 | 1.64 Mn |
| Jul 31, 2011 | 2.57 Mn |